Literature DB >> 15543565

Sensitive noninvasive marker for the diagnosis of probable bacterial or viral infection.

Saeed A Jortani1, Michael J Pugia, Ronald J Elin, Meera Thomas, Edward P Womack, Todd Cast, Roland Valdes.   

Abstract

Urinary trypsin inhibitor (uTi) is a product of elastase-mediated degradation of interleukin-alpha-inhibitor (I-alpha-I). Its activity increases in the urine of patients with a malignancy, inflammation, or infection, or in late pregnancy. The objective of this study was to compare the sensitivity of uTi in urine with that of serum quantitative C-reactive protein (CRP) for diagnosing infection, as indicated by white cell response and clinical assessment. Ninety controls and 171 patients with various systemic infections were enrolled. We measured uTi enzymatically on a Cobas Fara (Roche Diagnostics). Patients were separated into bacterial, probable bacterial, viral, or probable viral groups based on the results of a complete blood count with differential (CBC), urinalysis (UA), and clinical assessment. In the bacterial (n=70) and control (n=90) groups, the uTi values (mean+/-SE) were 25.3+/-3.1 mg/L and 2.8+/-0.8 mg/L, respectively. uTi (at 2.7 mg/L) had a diagnostic sensitivity of 91% and specificity of 82% (AUC=0.889), whereas CRP (at a cutoff of 10 mg/L) had a sensitivity and specificity of 82% and 96%, respectively (AUC=0.921). As a marker of infection (positive in both bacterial and viral groups), uTi had a sensitivity of 91% (AUC=0.884) vs. 89% (AUC=0.828) for CRP. Our data indicate that uTi has sufficient clinical sensitivity for screening systemic infections, and may have diagnostic value as a noninvasive test. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15543565      PMCID: PMC6807964          DOI: 10.1002/jcla.20040

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  19 in total

Review 1.  Procalcitonin as a marker of bacterial infection.

Authors:  D Gendrel; C Bohuon
Journal:  Pediatr Infect Dis J       Date:  2000-08       Impact factor: 2.129

2.  The excretion of trypsin inhibitor in urine during normal pregnancy.

Authors:  H J FAARVANG
Journal:  Acta Endocrinol (Copenh)       Date:  1959-05

3.  The plasminogen activator in urine and the urinary trypsin inhibitor.

Authors:  T ASTRUP; I STERNDORFF
Journal:  Scand J Clin Lab Invest       Date:  1955       Impact factor: 1.713

4.  Automated measurement of trypsin inhibitor in urine with a centrifugal analyzer: comparison with other acute phase reactants.

Authors:  S Kuwajima; T Matsui; S Kitahashi; T Kishida; T Noda; Y Izumi; K Naka; K Okuda
Journal:  Clin Biochem       Date:  1990-04       Impact factor: 3.281

5.  Effects of urinary trypsin inhibitor in patients at risk for premature labor with a bulging fetal membrane.

Authors:  Yoshio Matsuda; Naoki Yunohara
Journal:  Fetal Diagn Ther       Date:  2002 Mar-Apr       Impact factor: 2.587

6.  Plasma and urine levels of urinary trypsin inhibitor in patients with acute and fulminant hepatitis.

Authors:  Shi De Lin; Ryujin Endo; Akihiro Sato; Yasuhiro Takikawa; Kamon Shirakawa; Kazuyuki Suzuki
Journal:  J Gastroenterol Hepatol       Date:  2002-02       Impact factor: 4.029

7.  Assessment of the clinical value of urinary trypsin inhibitory activity in elderly people.

Authors:  M Merle; C Jeandel; F Belleville-Nabet; F Bertrand; F Penin; G Cuny; J B Dureux
Journal:  Age Ageing       Date:  1992-11       Impact factor: 10.668

8.  The uristatin dipstick is useful in distinguishing upper respiratory from urinary tract infections.

Authors:  Michael J Pugia; Ronald Sommer; Paul Corey; Linda Anderson; Shannon Gleason; Saeed A Jortani; Ronald J Elin; Darryl L Gopual; Roland Valdes; John A Lott
Journal:  Clin Chim Acta       Date:  2004-03       Impact factor: 3.786

9.  Urinary trypsin inhibitory activity for the diagnosis of bacterial infection: a prospective study in 690 patients.

Authors:  A M Piette; J Saba; N Bernard; M Pougheon; O Abat; J Fermanian; J C Piette; A Chapman
Journal:  Eur J Med       Date:  1992-09

10.  A system of cancer-related urinary glycoproteins: biochemical properties and clinical applications.

Authors:  D Rudman; R K Chawla; A D Wadsworth; D W Nixon; M Schwartz
Journal:  Trans Assoc Am Physicians       Date:  1977
View more
  5 in total

1.  Immunological evaluation of urinary trypsin inhibitors in blood and urine: role of N- & O-linked glycoproteins.

Authors:  Michael J Pugia; Saeed A Jortani; Manju Basu; Ronald Sommer; Hai-Hang Kuo; Solomon Murphy; Doug Williamson; James Vranish; Patrick J Boyle; Danny Budzinski; Roland Valdes; Subhash C Basu
Journal:  Glycoconj J       Date:  2007-01       Impact factor: 2.916

Review 2.  The Inter-α-Trypsin Inhibitor Family: Versatile Molecules in Biology and Pathology.

Authors:  Megan S Lord; James Melrose; Anthony J Day; John M Whitelock
Journal:  J Histochem Cytochem       Date:  2020-07-08       Impact factor: 2.479

3.  Emergence of single-molecule sequencing and potential for molecular diagnostic applications.

Authors:  Patrice M Milos
Journal:  Expert Rev Mol Diagn       Date:  2009-10       Impact factor: 5.225

4.  Utilization of electronic health records for the assessment of adiponectin receptor autoantibodies during the progression of cardio-metabolic comorbidities.

Authors:  Michael J Pugia; Meeta Pradhan; Rong Qi; Doreen L Eastes; Anna Vorsilak; Bradley J Mills; Zane Baird; Aruna Wijeratne; Scott M McAhren; Amber Mosley; Anantha Shekhar; Daniel H Robertson
Journal:  Arch Autoimmune Dis       Date:  2020

5.  Levels of Urinary Trypsin Inhibitor and Structure of Its Chondroitin Sulphate Moiety in Type 1 and Type 2 Diabetes.

Authors:  Antonio Junior Lepedda; Gabriele Nieddu; Silvia Rocchiccioli; Nadia Ucciferri; Michela Idini; Pierina De Muro; Marilena Formato
Journal:  J Diabetes Res       Date:  2018-02-06       Impact factor: 4.011

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.